Cost-Effectiveness of (177)Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations.
- DOI
- 10.2967/jnumed.126.272700
- Published
- 2026 Sep 3
- Container
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.2967/jnumed.126.272700,
title = {Cost-Effectiveness of (177)Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations.},
author = {Subramanian K and Osborne JR},
year = {2026},
journal = {Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
doi = {10.2967/jnumed.126.272700},
url = {https://doi.org/10.2967/jnumed.126.272700}
}RIS
TY - JOUR TI - Cost-Effectiveness of (177)Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations. AU - Subramanian K AU - Osborne JR PY - 2026 JO - Journal of nuclear medicine : official publication, Society of Nuclear Medicine DO - 10.2967/jnumed.126.272700 UR - https://doi.org/10.2967/jnumed.126.272700 ER -
APA
K, S., & JR, O. (2026). Cost-Effectiveness of (177)Lu-PSMA-617 Versus Cabazitaxel: Accounting for Real-World and Health Equity Considerations.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. https://doi.org/10.2967/jnumed.126.272700
Source records
- pubmed · retrieved 2026-09-26T11:00:57.915Z